1. The Ability to Use Epinephrine Autoinjector in Patients Who Receive Prescription Immediately after Anaphylaxis
- Author
-
Mitja Košnik and Sasa Kadivec
- Subjects
Adult ,Male ,Allergy ,medicine.medical_specialty ,Health Knowledge, Attitudes, Practice ,Epinephrine ,Immunology ,Pharmacy ,Injections ,medicine ,Immunology and Allergy ,Humans ,In patient ,Epinephrine autoinjector ,Medical prescription ,Anaphylaxis ,business.industry ,Anaphylactic reaction ,Anaphylactic reactions ,General Medicine ,Middle Aged ,medicine.disease ,Prescriptions ,Health Care Surveys ,Emergency medicine ,Female ,business - Abstract
Background: Epinephrine autoinjector (EAI) is prescribed to prevent a fatal outcome in the case of a repeated anaphylactic reactions. We wanted to determine how adult patients who received their first prescription as part of an urgent treatment of an anaphylactic reaction or at their family physician were instructed on the use of EAI. Methods: Nurses assessing patients’ knowledge asked the patient to demonstrate how to use the EAI training device. Patients who performed the critical steps correctly in 1 min were labelled as competent. Results: Forty-one patients (24% women, 46 ± 5 years) came for the allergy examination 116 ± 145 days after receiving a prescription for EAI. When prescribing, the doctor or nurse explained the instructions for the use of EAI to 63.4% patients, and 31.7 patients practiced the use of EAI using a training device. At the pharmacy, 22% received explanation and 7% also practiced using a training device. Fifty-four percent of patients were able to effectively administer EAI adrenaline within 1 min. Higher education level was associated with sufficient knowledge about the use of EAI (p = 0.026). At the time of the visit to the allergy specialist clinic, 61% of patients had EAI with them. The shelf life of EAI was known to 63% of patients. Conclusions: The activities to increase the prescription rate of EAI immediately after treatment of anaphylactic episode are not sufficient to prevent severe outcome after the repeated episodes of anaphylaxis as nearly a half of patients are not able to use EAI correctly.
- Published
- 2020